XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration, License, and Other Agreements - Other Collaboration and License Agreements (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Nov. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Collaboration, License, Promotion and Other Commercial Agreements            
Revenue   $ 97,231 $ 104,031 $ 194,760 $ 192,876  
Research and development expense   11,452 12,163 22,274 27,647  
Accrued research and development costs   6,338   6,338   $ 15,896
Collaborative arrangements revenue            
Collaboration, License, Promotion and Other Commercial Agreements            
Revenue   97,231 103,386 194,760 192,051  
Alnylam | Collaborative arrangement, co-promotion agreements            
Collaboration, License, Promotion and Other Commercial Agreements            
Revenue   585 596 1,408 1,052  
Alnylam | Royalty            
Collaboration, License, Promotion and Other Commercial Agreements            
Revenue   600 $ 600 1,400 $ 1,100  
COUR Pharmaceuticals Development Company, Inc.            
Collaboration, License, Promotion and Other Commercial Agreements            
Collaborative arrangement, upfront payment $ 6,000          
Collaborative arrangement, contingent payment, payable $ 13,500          
Collaborative arrangement, option to acquire license, exercise price, payable   35,000   35,000    
Collaborative arrangement, milestones. potential commercial milestone payments, term of agreement, payable   440,000   440,000    
Research and development expense           19,500
Accrued research and development costs   $ 3,800   $ 3,800   $ 13,500